ライフサイエンスコーパス: destination therapy

1 f pump support (bridge to transplantation or destination therapy).

2 eutic intention (bridge to transplant versus destination therapy).

3 ts who are not deemed transplant candidates (destination therapy).

4 ates in patients receiving these devices for destination therapy.

5 have been used and allow the possibility of destination therapy.

6 te II implantation, with 62% LVADs placed as destination therapy.

7 bridge to transplant, bridge to recovery or destination therapy.

8 nclude use of high-risk transplant lists and destination therapy.

9 e to transplantation, also called chronic or destination therapy.

10 idge to transplantation, may also be used as destination therapy.

11 n in the patients who received the device as destination therapy.

12 ts to provide support until transplant or as destination therapy.

13 ed for the patients who received the pump as destination therapy.

14 er LVAD and is associated with older age and destination therapy.

15 as a bridge to cardiac transplantation or as destination therapy.

16 s are now being used as a permanent form of "destination" therapy.

17 p = 0.001), had MCS more often implanted as destination therapy (33% vs. 14% vs. 22%, p = 0.03), req

18 port were bridge to transplantation (54%) or destination therapy (46%).

19 t devices are also being expanded to include destination therapy and alternatives to cardiac transpla

20 ics encouraged inclusion of all indications (destination therapy and bridge to transplant) and preven

21 end-stage heart disease as either bridge or destination therapy, and have significantly improved the

22 schemic cardiomyopathy, LVAD implantation as destination therapy, and increased baseline body mass in

23 rdiotomy shock, "bridge to transplant," and "destination therapy." At present, device development, cl

24 IIB/IV patients meeting indications for LVAD destination therapy but not dependent on intravenous ino

25 ridge to transplantation (BTT) (n = 281) and destination therapy (DT) (n = 374) trials were analyzed.

26 f left ventricular assist devices (LVADs) as destination therapy (DT) can provide survival superior t

27 The HeartMate II (HMII) destination therapy (DT) trial demonstrated significant

28 A post-approval (PA) study for destination therapy (DT) was required by the Food and Dr

29 with MCSs for bridge to transplant (BTT) and destination therapy (DT).

30 ation of a left ventricular assist device as destination therapy (DT).

31 spital mortality with pulsatile flow LVAD as destination therapy (DT).

32 ability of left ventricular assist device as destination therapy (DT-LVAD) to prolong survival for ma

33 ved 145 devices as a bridge to transplant or destination therapy for advanced heart failure.

34 but currently have too many limitations for destination therapy for children.

35 n has led to their evaluation as a long-term destination therapy for end-stage heart disease.

36 state of knowledge and future directions of Destination Therapy for end-stage heart failure.

37 ss associated with continuous-flow LVADs for destination therapy has improved significantly relative

38 splantation and, more recently, as a form of destination therapy has provided a great opportunity to

39 orporation, Pleasanton, California) LVAD for destination therapy has provided an attractive option fo

40 ernative to heart transplantation, so-called Destination Therapy, has become a promising new option f

41 ence interval 1.46-3.44; P(trend)<0.001) and destination therapy (hazard ratio, 1.42; 95% confidence

42 pproved for use as a bridge-to-transplant or destination therapy in patients who have irreversible en

43 tance devices are now used increasingly as a destination therapy in patients with advanced heart fail

44 , both as a bridge to transplantation and as destination therapy in those who are ineligible for card

45 4 patients (all men; mean age 62.8 years) as destination therapy (in the United Kingdom).

46 entification of a dedicated caregiver before destination therapy left ventricular assist device (DT L

47 Destination therapy left ventricular assist devices (DT

48 ge to transplantation and more recently as a destination therapy, left ventricular assist device supp

49 Patients who instead received destination therapy-LVAD are estimated to live 4.4 years

50 Destination therapy-LVAD significantly improves life exp

51 s or improved quality of life are needed for destination therapy-LVAD to be cost effective.

52 ejection fraction was 18.1%, and 66.7% were destination therapy LVADs.

53 HMII bridge to transplantation (n = 405) and destination therapy (n = 551) clinical trials were retro

54 It has already been approved for destination therapy of heart failure, and greater portab

55 T), left ventricular assist device (LVAD) as destination therapy or bridge to transplant.

56 ntinuous-flow LVADs as bridge to transplant, destination therapy, or bridge to decision from January

57 e, either as a bridge to transplantation, as destination therapy, or in some patients, as a bridge to

58 is study sought to assess the utility of the Destination Therapy Risk Score (DTRS) in patients with c

59 ival Score, Seattle Heart Failure Model, and Destination Therapy Risk Score may provide guidance for

60 rability and complications, the potential of Destination Therapy should continue to expand through th

61 ailure and the expanded indication use (i.e. destination therapy), the overall number of implanted pa

62 In a recent destination therapy trial, survival in LVAD patients was

63 into the HMII bridge to transplantation and destination therapy trials (N = 1,122) were randomly div

64 t of either the bridge to transplantation or destination therapy trials at a community hospital.

65 effectiveness of continuous-flow devices for destination therapy versus optimal medical management in

66 oncerning survival and quality of life since destination therapy was first introduced 10 years ago.

67 ear survival rate for patients supported for destination therapy with a continuous-flow LVAD is 74%,

68 Destination therapy with a left ventricular assist devic